LO FRANCIS 4

What Happened

• Lo Francis, Chief People Officer of Adaptive Biotechnologies (ADPT), was granted 44,063 shares on March 4, 2026. The Form 4 reports the acquisition as an award/grant (transaction code A) at $0.00 per share, so the reported consideration is $0.
• This is an award (compensation-related grant), not an open-market purchase or sale — awards are common as part of executive pay and do not necessarily signal an immediate personal cash investment.

Key Details

• Transaction date: 2026-03-04; Form 4 filed: 2026-03-06 (filed within the typical two-business-day window).
• Transaction type/code: Award/Grant (A); price per share reported: $0.00; reported cash consideration: $0.
• Shares owned after the reported transaction: not specified in the information provided on this filing.
• No 10b5-1, tax-withholding, or cashless-sell footnotes were reported in the provided transaction details.

Context

• Awards like this are usually part of compensation packages (e.g., restricted stock or RSUs that may vest over time). They differ from market purchases or sales and should be interpreted as compensation, not a direct market endorsement.
• For retail investors, track subsequent Form 4s that show vesting, sales, or withholding (which can convert awards into fewer net shares) to see the ultimate economic impact on the insider’s holdings.